Apellis Pharmaceuticals, Inc.

Waltham, MA 100 5th Avenue, Waltham, MA 0245

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company’s lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver.

Click to rate this company
[Total: 0 Average: 0]

3.8

Overall Excellence Rating

Industry

Healthcare

Category

Biotech & Pharmaceuticals

ESG/Ethical Impact

Apellis’ focus on drug development could indirectly contribute to environmental sustainability by advancing treatments that improve patients’ health and reduce the overall burden on healthcare systems. Sustainable Practices: The company might focus on efficient use of resources in its operations, such as energy-efficient facilities and sustainable supply chain practices.Apellis’ core business of developing therapies could have a significant positive impact on patient health and well-being, addressing unmet medical needs. Healthcare Access: The company’s focus on rare diseases could contribute to accessible and advanced healthcare solutions for underserved patient populations.Clinical Standards: Adherence to ethical and clinical standards is essential for maintaining patient trust and regulatory compliance in drug development. Transparency: Apellis’ commitment to transparency and ethical conduct likely reflects in its corporate governance practices.Apellis’ financial sustainability comes from the development and potential commercialization of innovative therapies. Investor Relations: The company’s ESG efforts can influence investor perception, especially for those seeking investments aligned with ethical healthcare innovations.The company’s ESG initiatives can resonate with investors interested in both financial returns and ethical medical advancements.Apellis’ therapies directly impact patient lives by addressing serious medical conditions and improving health outcomes.

Eligible Awards

Coming Soon

Claim Your Award Badges

Do you work with Us

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer.

Awards Received

2023

Revenues

$75,000,000.00

Website Traffic

Employee Rating

3.6

Customer Rating

4.6

Company Size

100-1000

ESG Risk Rating

3

We’re Happy to Help.

Do you have questions about your ranking, our projects, or why you’re not on the list?
Scroll to Top

Excellence In My Industry

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business in your specific industry – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best Practice Certified

This badge tells your customers, employees, partners, and other stakeholders that your company has met the criteria of our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Best of Best Practices

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the top 20 companies in your industry that has met the criteria for our excellence certification in best practices across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.

Newsweek Excellence 1000

This badge tells your customers, employees, partners, and other stakeholders that your company is one of the Top 1000 companies that demonstrate excellence across all pillars of business – from financial responsibility and results, sustainability, social responsibility, employee experience, customer satisfaction, ethics, and more.